keine Finanzberatung

SMMT · Summit Therapeutics Inc.

Oncology biotech developing ivonescimab, licensed from Akeso

Risiko 9/10 · EXTREME RISK · one-drug binary bet · $17.61 ▲ 2.77%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $17.61
  • Market cap $14.0B
  • P/E (ttm) n/a
  • Div yield none
  • 52-wk range $12.07 – $29.23

Wichtigste Risiken

  • Western survival data fails to confirm the China results (Shareholders) — EXTREME
  • Pre-revenue valuation with no earnings support (Shareholders) — EXTREME
  • Dependence on partner Akeso for the asset and its data (Shareholders) — HIGH
  • Funding needs for a sprawling global trial program (Shareholders) — MED

Fazit

The nine-figure insider buying signals real conviction, but this remains a binary bet on one drug's Western survival data.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.